Beyond the binary terminal effector or memory outcomes conceived thus far, it is enticing to speculate whether rheostatic regulation of MPEC and SLEC differentiation states by controlling IL-2 signals might be exploited to balance the immediate therapeutic benefits and long-term protective outcomes during adoptive T cell therapy and therapeutic cancer vaccines. Here, IL2 is linked to cancer.